Please assess the completion status of the following clinical trial:

Trial Title: Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be at least 19 years of age and older~* Ability to give informed consent and attend the study visits~* Patients with established diagnosis of retinal vascular diseases (diabetic macular edema, neovascular macular degeneration,presumed ocular histoplasmosis syndrome, high myopia) who require intravitreal injection of anti-VEGF drugs such as bevacizumab,ranibizumab or aflibercept and are likely to need three monthly doses.~* Patients who have not received intravitreal injections within 3 months of study entry~* No previous established diagnosis of glaucoma and consequently no previous history of Argon Laser Trabeculoplasty (ALT) or Selective Laser Trabeculoplasty (SLT).~* No previous history of ocular surgery~* Patients who are not planning on and are unlikely to require an elective ocular surgical or laser procedure within the study duration~* Open angle of the anterior chamber on clinical examination~* Ability to cooperate for aqueous humor dynamic studies~* Contact lenses removed prior to topical fluorescein instillation, and not used until the end of each fluorophotometry session~* Able to participate on site over the multi-visit study period~Exclusion Criteria:~* Age less than 18 years of age~* Women who are pregnant or nursing~* Ocular hypertension or glaucoma~* Narrow angle with complete or partial closure (gonioscopy angle \<2)~* Any previous surgical or laser procedures~* Secondary glaucoma including pigmentary, exfoliative, uveitic and traumatic glaucomas~* Any active neovascularization of the iris, angle, disc or retina~* Diagnosis of retinal arterial or vein occlusion~* Chronic or recurrent inflammatory eye disease~* Ocular trauma within the past 6 months~* Ocular infection or ocular inflammation in the past 2 months~* Any abnormality preventing reliable fluorophotometry of either eye,such as corneal scarring or severe dry eye that results in punctuate fluorescein staining of the cornea~* Intraocular surgery within 6 months~* Serious hypersensitivity to any components of the study medications or risk from treatment with glaucoma medications, such as severe asthma or emphysema.~* Use of any glucocorticoid by any route. Subject must be washed out of the glucocorticoid for at least 2 weeks before study entry.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).